Physicians

Departments / Divisions

• Radiation Oncology / Radiation Onc-Clinical Sup
• Surgery / Urology

Address
DUMC 3085
Durham, NC 27710

Appointment Telephone
919-660-2100

Office Telephone
919-668-5640

Fax Telephone
919-668-7345

Training

• MD, University of Virginia School of Medicine, 1989

Residency

• Radiation Oncology, Shands at the University of Florida, 1993

Other Training

• MS, Clinical Epidemiology, Wake Forest University (North Carolina), 2000
• MEd, Adult Education, Penn State University, 2006

Clinical Interests
Treatment of genitourinary cancers (prostate, bladder) with radiotherapy, prostate brachytherapy, intensity-modulated radiation therapy

Research Interests
Prostate cancer, Intensity-modulated radiation therapy (IMRT), Image-guided radiation therapy (IGRT), Stereotactic Body Radiation Therapy (SBRT), Prostate HDR and LDR Brachytherapy, Quality of Life, Educational Technology

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• ASTRO
• UpToDate

Representative Publications
Lawton, CA; Michalski, J; El-Naqa, I; Buyyounouski, MK; Lee, WR; Menard, C; O'Meara, E; Rosenthal, SA; Ritter, M; Seider, M. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. International Journal of Radiation: Oncology - Biology - Physics. 2009;74:383-387. (2009) Abstract

Lawton, CA; Michalski, J; El-Naqa, I; Kuban, D; Lee, WR; Rosenthal, SA; Zietman, A; Sandler, H; Shipley, W; Ritter, M; Valicenti, R; Catton, C; Roach, M; Pisansky, TM; Seider, M. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. International Journal of Radiation: Oncology - Biology - Physics. 2009;74:377-382. (2009) Abstract

Lee, WR. Extreme hypofractionation for prostate cancer. Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care. 2009;9:61-65. (2009) Abstract

Lee, WR. The ethics of hypofractionation for prostate cancer. International Journal of Radiation: Oncology - Biology - Physics. 2009;73:969-970. (2009) Abstract

Lee, WR. Technology assessment: vigilance required. International Journal of Radiation: Oncology - Biology - Physics. 2008;70:652-653. (2008) Abstract

Miles, EF; Lee, WR. Hypofractionation for prostate cancer: a critical review. Seminars in Radiation Oncology. 2008;18:41-47. (2008) Abstract

Rossi, PJ; Urbanic, J; Clark, PE; McCullough, DL; Lee, WR. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. Brachytherapy. 2008;7:286-289. (2008) Abstract

Wu, QJ; Thongphiew, D; Wang, Z; Mathayomchan, B; Chankong, V; Yoo, S; Lee, WR; Yin, FF. On-line re-optimization of prostate IMRT plans for adaptive radiation therapy. Physics in Medicine and Biology. 2008;53:673-691. (2008) Abstract

Lawton, CA; DeSilvio, M; Lee, WR; Gomella, L; Grignon, D; Gillin, M; Morton, G; Pisansky, T; Sandler, H. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). International Journal of Radiation: Oncology - Biology - Physics. 2007;67:39-47. (2007) Abstract

Lee, WR. Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction. Future Oncology. 2007;3:649-654. (2007) Abstract

Lee, WR; Bae, K; Lawton, C; Gillin, M; Morton, G; Firat, S; Baikadi, M; Kuettel, M; Greven, K; Sandler, H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007;109:1506-1512. (2007) Abstract

Lee, WR; Sharkey, J; Cowan, JE; DuChane, J; Carroll, PR; CaPSURE Investigators. Prostate brachytherapy: a descriptive analysis from CaPSURE. Brachytherapy. 2007;6:123-128. (2007) Abstract

Papagikos, MA; Rossi, PJ; Urbanic, JJ; deGuzman, AF; McCullough, DL; Clark, PE; Lee, WR. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. American Journal of Clinical Oncology: cancer clinical trials. 2007;30:199-204. (2007) Abstract

Phillips, JJ; Hall, MC; Lee, WR; Clark, PE. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?. Urologic Oncology: seminars and original investigations. 2007;25:196-200. (2007) Abstract

Yacoub, J; Richardson, C; Farmer, M; Lee, WR; Clark, PE; Hurt, G; Levine, EA. Male breast cancer during treatment with leuprolide for prostate cancer. Clinical Advances in Hematology and Oncology. 2007;5:555-556. (2007) Abstract

Clark, PE; Hall, MC; Borden, LS; Miller, AA; Hu, JJ; Lee, WR; Stindt, D; D'Agostino, R; Lovato, J; Harmon, M; Torti, FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006;67:1257-1261. (2006) Abstract

Lee, WR. Computer-based learning in medical education: a critical view. Journal of the American College of Radiology. 2006;3:793-798. (2006) Abstract

Lee, WR; Bae, K; Lawton, CA; Gillin, MT; Morton, G; Firat, S; Baikadi, M; Kuettel, M; Greven, K; Sandler, H. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy. 2006;5:239-243. (2006) Abstract

Lee, WR; DeSilvio, M; Lawton, C; Gillin, M; Morton, G; Firat, S; Baikadi, M; Kuettel, M; Greven, K; Sandler, H. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. International Journal of Radiation: Oncology - Biology - Physics. 2006;64:804-809. (2006) Abstract

Lee, WR; Moul, JW. Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?. Nature Clinical Practice Oncology. 2006;3:534-535. (2006) Abstract

Rossi, PJ; Clark, PE; Papagikos, MA; McCullough, DL; Lee, WR. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology. 2006;67:349-353. (2006) Abstract

Urbanic, JJ; Lee, WR. Confidence intervals and survival estimates: a systematic review of 3 oncology journals. American Journal of Clinical Oncology: cancer clinical trials. 2006;29:405-407. (2006) Abstract

Urbanic, JJ; Lee, WR. Update on brachytherapy in localized prostate cancer: the importance of dosimetry. Current Opinion in Urology. 2006;16:157-161. (2006) Abstract

Feigenberg, SJ; Lee, WR; Desilvio, ML; Winter, K; Pisansky, TM; Bruner, DW; Lawton, C; Morton, G; Baikadi, M; Sandler, H. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. International Journal of Radiation: Oncology - Biology - Physics. 2005;62:956-964. (2005) Abstract

Lee, WR. Is NNT AOK?. International Journal of Radiation: Oncology - Biology - Physics. 2005;61:640-641. (2005) Abstract

Lee, WR. What variables predict for metastasis in men with biochemical relapse following radiotherapy for prostate cancer?. Nature Clinical Practice Oncology. 2005;2:340-341. (2005) Abstract

Papagikos, MA; Deguzman, AF; Rossi, PJ; McCullough, DL; Clark, PE; Lee, WR. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?. Brachytherapy. 2005;4:252-258. (2005) Abstract

Lee, WR. Changes in graduate medical education: a view from radiation oncology. Journal of the American College of Radiology. 2004;1:576-582. (2004) Abstract

Lee, WR. In regards to Wallner et al: (125)I versus (103)PD for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial (Int J Radiat Oncol Biol Phys 2003;57:1297-1303). International Journal of Radiation: Oncology - Biology - Physics. 2004;59:319. (2004) Abstract

Lee, WR. Medical malpractice and prostate brachytherapy. Brachytherapy. 2004;3:237-239. (2004) Abstract

Lee, WR. Permanent prostate brachytherapy: the significance of postimplant dosimetry. Reviews in Urology. 2004;6 Suppl 4:S49-S56. (2004) Abstract

Lee, WR. Re: Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol. 2003 Sep;68(3):295-7. Radiotherapy and Oncology. 2004;70:209-210. (2004) Abstract

McMullen, KP; deGuzman, AF; McCullough, DL; Lee, WR. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience. Urology. 2004;63:1128-1131. (2004) Abstract

Lee, WR. In regard to Ghaly et al., IJROBP 2003;55:1288-1293. International Journal of Radiation: Oncology - Biology - Physics. 2003;57:1198. (2003) Abstract

Lee, WR; Moughan, J; Owen, JB; Zelefsky, MJ. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer. 2003;98:1987-1994. (2003) Abstract

McMullen, KP; Lee, WR. A structured literature review to determine the use of the American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure. Urology. 2003;61:391-396. (2003) Abstract

Carroll, PR; Kantoff, PW; Balk, SP; Brown, MA; D'amico, AV; George, DJ; Grossfeld, GD; Johnson, CS; Kelly, WK; Klotz, L; Lee, WR; Lubeck, DP; Mcleod, DG; Oh, WK; Pollack, A; Sartor, O; Smith, MR; Hart, C; Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002;60:1-6. (2002) Abstract

Kiteley, RA; Lee, WR; deGuzman, AF; Mirzaei, M; McCullough, DL. Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. Brachytherapy. 2002;1:90-94. (2002) Abstract

Lee, WR. In regard to Brenner et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio) similar to late-responding normal tissue. International Journal of Radiation: Oncology - Biology - Physics. 2002;53:1392. (2002) Abstract

Lee, WR. Quality of life after prostate cancer treatment. Journal of Clinical Oncology. 2002;20:3038. (2002) Abstract

Lee, WR. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology. 2002;60:39-44. (2002) Abstract

Lee, WR; Roach, M; Michalski, J; Moran, B; Beyer, D. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. International Journal of Radiation: Oncology - Biology - Physics. 2002;54:457-461. (2002) Abstract

Lee, WR; deGuzman, AF; Tomlinson, SK; McCullough, DL. Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. Radiotherapy and Oncology. 2002;65:123-127. (2002) Abstract